Computational prospecting finds bifunctional antibiotic leads

Social posts circulating this week pointed to an older paper, not a new journal publication. The underlying study was published in *Science* on May 27, 2022 by Zongqiang Wang, Bimal Koirala, Yozen Hernandez, Matthew Zimmerman and Sean F. Brady. The paper described the discovery and synthesis of cilagicin, a “naturally inspired” bifunctional lipopeptide antibiotic identified through bioinformatic analysis of a bacterial gene cluster. (ncbi.nlm.nih.gov) The work matters because it combined computation with wet-lab validation rather than relying on a conventional screen of cultured microbes alone. (ncbi.nlm.nih.gov) The authors wrote that they used detailed bioinformatic analysis of the *cil* biosynthetic gene cluster to predict the compound and then chemically synthesized it. (eurekalert.org) AAAS said the compound showed broad activity against several Gram-positive bacteria in laboratory tests, including resistant strains. ### So what exactly did the researchers find? The *Science* paper identified cilagicin as the lead compound from the team’s prospecting effort. The authors reported that cilagicin is a lipopeptide antibiotic and said it was discovered from analysis of an uncharacterized biosynthetic gene cluster rather than isolated first as a known natural product. (ncbi.nlm.nih.gov) AAAS said Wang and colleagues analyzed nearly 10,000 bacterial genomes and found a distinct lipopeptide biosynthetic gene cluster in the soil bacterium *Paenibacillus mucilaginosus*. They then used bioinformatic algorithms to predict candidate compounds encoded by that cluster and synthesized those candidates for testing. (ncbi.nlm.nih.gov) ### What does “bifunctional” mean here? The paper said cilagicin sequesters “two distinct, indispensable undecaprenyl phosphates” used in bacterial cell-wall biosynthesis. That is the basis for calling it bifunctional: the molecule engages two related but distinct lipid carriers involved in an essential pathway. (ncbi.nlm.nih.gov) AAAS summarized the mechanism as inhibition of cell-wall biosynthesis leading to bacterial cell death. In the paper, the authors linked cilagicin’s activity and low observed resistance potential to that dual targeting strategy. ### Which bacteria did cilagicin work against? AAAS said cilagicin showed potent and broad antimicrobial activity against several Gram-positive bacteria in laboratory testing. (eurekalert.org) The release specifically named *Clostridioides difficile* and vancomycin-resistant enterococci among the difficult-to-treat resistant strains included in those tests. The paper itself described cilagicin as an appealing candidate against antibiotic-resistant pathogens because the authors did not detect resistance in their laboratory tests and also did not find detectable resistance among multidrug-resistant clinical isolates they examined. (ncbi.nlm.nih.gov) ### Why are people talking about it again now? X posts in the last 48 hours appear to be resurfacing the 2022 study, often through screenshots or secondary summaries rather than direct links to the journal article. The paper’s DOI is 10.1126/science.abn4213, and the publication date is May 27, 2022. That means the current social-media discussion is better understood as renewed attention to a previously published result than as a fresh antibiotic announcement. (eurekalert.org) The underlying source document is the *Science* paper by Wang and colleagues. ### What would have to happen before this becomes a drug? (ncbi.nlm.nih.gov) Ryan Seipke, writing in a related Perspective cited by AAAS, said the next major steps are absorption, distribution, metabolism, excretion and toxicity studies. AAAS said those studies could show whether further structural optimization is needed before any entry into clinical trials. The clearest next checkpoint remains preclinical development, not a near-term approval filing. (ncbi.nlm.nih.gov) As of the sources reviewed here, the verifiable record is the May 2022 *Science* article and the accompanying AAAS summary describing the follow-on studies needed before clinical testing. (eurekalert.org)